Vibegron
Vibegron is a selective beta-3 adrenergic receptor agonist that activates β3 receptors in bladder smooth muscle (detrusor), causing relaxation and increasing bladder capacity while reducing urinary urgency and frequency without affecting bladder contractility during voiding. It is approved for overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. As a β3 agonist, it offers an alternative mechanism to antimuscarinics with potentially fewer systemic anticholinergic side effects.
分子量
444.5000 g/mol
LogP
1.80
TPSA
94.00 Ų
リピンスキーの五則
適合
治療領域
作用機序
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
2D構造
Cite this structure
Embed this structure
SMILES
O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)[C@@H]1CCc2nccc(=O)n21
InChI
InChI=1S/C26H28N4O3/c31-24-14-15-27-23-13-12-22(30(23)24)26(33)29-19-8-6-17(7-9-19)16-20-10-11-21(28-20)25(32)18-4-2-1-3-5-18/h1-9,14-15,20-22,25,28,32H,10-13,16H2,(H,29,33)/t20-,21+,22-,25+/m0/s1
Molecular Formula
C26H28N4O3
HBD / HBA
3 / 5
回転可能結合数
6
重原子数
33
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
Vibegron is a selective beta-3 adrenergic receptor agonist that activates β3 receptors in bladder smooth muscle (detrusor), causing relaxation and increasing bladder capacity while reducing urinary urgency and frequency without affecting bladder contractility during voiding. It is approved for overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. As a β3 agonist, it offers an alternative mechanism to antimuscarinics with potentially fewer systemic anticholinergic side effects.
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Yes, Vibegron is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2107826. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 44472635. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="vibegron"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/vibegron/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/vibegron/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/vibegron/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="vibegron"></drugfyi-drug>